Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: a time series study based on national surveillance data thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
DER SPIEGEL
Suche öffnen
The Third Wave
Coronavirus Mutants Are Spreading Fast
The coronavirus mutants are spreading at breakneck speed in Germany. They have left puzzled researchers asking what makes them so highly infectious? And why are they infecting so many young people in Israel?
Maja Hitij / Getty Images
We can t take it anymore, raged Sonja Ultsch in a video on Facebook last week. We ve already let them slap us on the left cheek for Ischgl, now we have to turn our right cheek, too! It was a reference to the Austrian ski town that was responsible for one of the biggest outbreaks of the novel coronavirus in Europe during the first wave last year.
New SARS-CoV-2 neutralizing antibody enters clinical phase 7thspace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 7thspace.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim: New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and prevention
BI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical research
Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF s expertise in virology, immunology and clinical investigation with Boehringer
Credit: NIAID
Cologne, Marburg, Braunschweig and Ingelheim, Germany, 18 December 2020 - Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim s expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19.
Virus neutralizing antibodies are expected to become an important line of defense against SARS-CoV-2, complementing vaccines and nonpharmaceutical interventions. They are being investigated as a therapy option for individuals with mild or severe infections, but also as prevention or prophylaxis in non-infected people with a high risk of